We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
1
Edgewise Therapeutics
EWTX
$4.64B
$631M 11.68%
15,518,492
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$4.24B
$344M 6.37%
6,776,632
-1,182,906
-15% -$50.2M
LLY icon
3
Eli Lilly
LLY
$1.05T
$309M 5.73%
257,900
+21,100
+9% +$21.6M
MBX
4
MBX Biosciences
MBX
$3.03B
$189M 3.51%
3,428,736
-209,151
-6% -$7.3M
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$184M 3.42%
2,718,735
– –
AZN icon
6
AstraZeneca
AZN
$252B
$171M 3.17%
915,700
+245,500
+37% +$46.2M
GPCR icon
7
Structure Therapeutics
GPCR
$3.38B
$119M 2.2%
2,209,400
+733,997
+50% +$32.5M
SION
8
Sionna Therapeutics
SION
$265M
$112M 2.08%
2,555,877
-974,825
-28% -$39M
CRVS icon
9
Corvus Pharmaceuticals
CRVS
$1.19B
$107M 1.98%
7,165,006
– –
AVBP icon
10
ArriVent BioPharma
AVBP
$1.49B
$105M 1.95%
3,027,328
– –
GH icon
11
Guardant Health
GH
$21.7B
$87.6M 1.62%
583,700
+148,500
+34% +$16.2M
ARGX icon
12
argenx
ARGX
$64B
$86.2M 1.6%
92,880
-44,020
-32% -$36.3M
MRK icon
13
Merck
MRK
$366B
$85.2M 1.58%
663,400
– –
QURE icon
14
uniQure
QURE
$3.38B
$83.3M 1.54%
1,807,486
-328,663
-15% -$8.6M
PRAX icon
15
Praxis Precision Medicines
PRAX
$9.63B
$77M 1.43%
230,100
+57,600
+33% +$18.2M
EW icon
16
Edwards Lifesciences
EW
$52B
$75.5M 1.4%
834,900
-395,700
-32% -$33.1M
PRLD icon
17
Prelude Therapeutics
PRLD
$437M
$73.2M 1.36%
13,724,571
+2,815,315
+26% +$12.3M
ABVX
18
Abivax
ABVX
$9.89B
$72.8M 1.35%
546,522
+80,822
+17% +$9.15M
DYN icon
19
Dyne Therapeutics
DYN
$4.68B
$71.9M 1.33%
3,235,684
+317,800
+11% +$5.91M
NTRA icon
20
Natera
NTRA
$47B
$71.1M 1.32%
262,000
– –
CGON icon
21
CG Oncology
CGON
$6.59B
$69.1M 1.28%
972,800
+24,533
+3% +$1.6M
UNH icon
22
UnitedHealth
UNH
$353B
$67M 1.24%
+161,100
New +$59.7M
SPRY icon
23
ARS Pharmaceuticals
SPRY
$586M
$66.4M 1.23%
8,288,510
– –
ASND icon
24
Ascendis Pharma A/S
ASND
$16.3B
$65.2M 1.21%
244,456
+62,479
+34% +$14.6M
HUM icon
25
Humana
HUM
$46.3B
$65.2M 1.21%
+164,100
New +$46.7M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.